SGMO - サンガモ・セラピュ―ティクス （Sangamo Therapeutics Inc.）

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at …

According to Benzinga Pro data, during Q4, Sangamo Therapeutics (NASDAQ: SGMO ) posted sales of $27.23 million. Earnings were up 2.22%, but Sangamo Therapeutics still reported an overall loss of $51.97 million. In Q3, Sangamo Therapeutics brought in $26.46 million in sales but lost $53.16 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com

https://www.investing.com/news/pro/sangamo-bioscienc-receives-investment-bank-analyst-rating-update-3069038

Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) was downgraded by investment analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research note issued on Friday, The Fly reports. They currently have a $1.50 target price on the biopharmaceutical company’s stock, down from their previous target price of $5.00. Bank of […]

BofA Securities has downgraded Sangamo Therapeutics (SGMO) to underperform as the company is undergoing a restructuring to address cash concerns. Read more here.

As of Wednesday, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock closed at $3.33, up from $3.14 the previous day. While Sangamo Therapeutics Inc. has overperformed by 5.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -57.48%, with highs and lows ranging from $7.99 to $2.72, […]

Sangamo Therapeutics Inc. (SGMO)’s stock is trading at $3.04 at the moment marking a rise of 9.35% from the last session close. As of this writing, shares are priced at -62.84% less than their 52-week high of $8.18, and 11.72% over their 52-week low of $2.72. Based on the past 30-day period, the stock price […]

In the last trading session, 1.61 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.13. With the company’s per share price at $3.10 changed hands at $0.01 or 0.32% during last session, the market valuation stood at $487.35M. SGMO’s last price was a discount, traded about -179.03% off its 52-week … SGMO Stock: More Upside For Sangamo Therapeutics Inc. (NASDAQ: SGMO)? Read More »

Gainers: Sanofi (SNY) +6%. Atlis Motor Vehicles (AMV) +5%

In Thursday’s session, Sangamo Therapeutics Inc. (NASDAQ:SGMO) marked $3.30 per share, down from $3.45 in the previous session. While Sangamo Therapeutics Inc. has underperformed by -4.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -57.42%, with highs and lows ranging from $8.65 to […]

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price closed higher on Tuesday, September 27, jumping 4.81% above its previous close. A look at the daily price movement shows that the last close reads $4.78, with intraday deals fluctuated between $4.84 and $5.05. The company’s 5Y monthly beta was ticking 1.44. Taking into account the 52-week price action we … Looking For A Good Stock? Let This Sangamo Therapeutics Inc. (NASDAQ: SGMO) Analysis Help. Read More »

In the last trading session, 1.05 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $4.78 changed hands at -$0.17 or -3.43% during last session, the market valuation stood at $761.88M. SGMO’s last price was a discount, traded about -140.38% off its 52-week … Sangamo Therapeutics Inc. (NASDAQ: SGMO) Is Rated A Buy By Analysts. Read More »

A phase 3 trial of Pfizer (PFE) and Sangamo Therapeutics (SGMO) Therapeutics'' giroctocogene fitelparvovec, a gene therapy for hemophilia A, has reopened recruitment.Dosing is expected…

As of Tuesday, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock closed at $5.30, down from $5.31 the previous day. While Sangamo Therapeutics Inc. has underperformed by -0.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SGMO fell by -42.89%, with highs and lows ranging from $11.49 to $3.12, […]

Sangamo Therapeutics Inc. (NASDAQ:SGMO) has a beta value of 1.29 and has seen 1.76 million shares traded in the last trading session. The company, currently valued at $918.36M, closed the last trade at $5.31 per share which meant it gained $0.06 on the day or 1.14% during that session. The SGMO stock price is -116.38% … Weak Fundamental Momentum Sinks Sangamo Therapeutics Inc. Read More »